Werewolf Therapeutics Inc
werewolftx.comWerewolf Therapeutics Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company developing conditionally activated immunotherapy product candidates for the treatment of cancer. The company generates no product revenue and funds operations through external financing, having reported recurring losses from operations and disclosed substantial doubt about its ability to continue as a going concern as of the 10-K filed March 27, 2026. Its pipeline includes WTX-124 and WTX-330, both in Phase 1/1b or Phase 1b/2 clinical trials as of early 2025, as well as WTX-721 and JZP898, the latter subject to a Transfer Agreement with Jazz Pharmaceuticals. Research and development spending decreased year-over-year in FY2025 due to lower manufacturing costs across WTX-330, WTX-124, WTX-721, and JZP898, partially offset by increased clinical trial costs tied to ongoing enrollment. The company competes against major pharmaceutical, specialty pharmaceutical, and biotechnology companies developing immunotherapies for cancer. Daniel Hicklin, a founder, serves as President and Chief Executive Officer.
Products & Services
Pipeline product candidates include WTX-124 (Phase 1/1b clinical trial ongoing as of FY2025), WTX-330 (Phase 1b/2 clinical trial initiated in Q1 2025), WTX-721 (IND-enabling studies conducted in FY2024), and JZP898 (subject to a Transfer Agreement with Jazz Pharmaceuticals). All candidates are conditionally activated immunotherapies targeting cancer.
Revenue Model
Pre-revenue clinical-stage company. No product sales as of FY2025. Operations are funded through external financing. Potential future revenue streams include product sales, licensing, or partnership arrangements, but none are disclosed as active in the filing excerpts.
Customers & Markets
No commercial customers as of FY2025. End market is oncology, specifically immunotherapy for cancer treatment.
Financial Snapshot
Loading...
